5KW Stock Overview
A life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
SkinBioTherapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.17 |
| 52 Week High | UK£0.20 |
| 52 Week Low | UK£0.063 |
| Beta | 1.75 |
| 11 Month Change | 14.47% |
| 3 Month Change | 39.20% |
| 1 Year Change | -14.71% |
| 33 Year Change | -70.76% |
| 5 Year Change | n/a |
| Change since IPO | -35.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5KW | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.0% | -0.7% | -0.02% |
| 1Y | -14.7% | -17.2% | 8.2% |
Return vs Industry: 5KW exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 5KW underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 5KW volatility | |
|---|---|
| 5KW Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5KW's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5KW's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 11 | Stuart Ashman | www.skinbiotherapeutics.com |
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.
SkinBioTherapeutics plc Fundamentals Summary
| 5KW fundamental statistics | |
|---|---|
| Market cap | €43.98m |
| Earnings (TTM) | -€3.47m |
| Revenue (TTM) | €194.51k |
226.1x
P/S Ratio-12.7x
P/E RatioIs 5KW overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5KW income statement (TTM) | |
|---|---|
| Revenue | UK£161.65k |
| Cost of Revenue | UK£59.97k |
| Gross Profit | UK£101.68k |
| Other Expenses | UK£2.99m |
| Earnings | -UK£2.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 62.90% |
| Net Profit Margin | -1,784.72% |
| Debt/Equity Ratio | 0% |
How did 5KW perform over the long term?
See historical performance and comparison